Products for Research Use Only
RegisterLogin

Serdemetan

CAT: 0804-HY-12025-01Size: 5 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-12025-01Size:5 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
Serdemetan (JNJ-26854165) is a potent anticancer agent with radiosensitizing activity. Serdemetan exhibits antiproliferative activity in various p53 wild-type tumor cells. Serdemetan also antagonizes the Mdm2-HIF1α axis leading to decreased levels of glycolytic enzymes[1][2][3].
CAS Number
881202-45-5
Product Name Alternative
JNJ-26854165
UNSPSC
12352005
Hazard Statement
H315, H319, H320
Target
Apoptosis; E1/E2/E3 Enzyme; MDM-2/p53
Type
Reference compound
Related Pathways
Apoptosis; Metabolic Enzyme/Protease
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/Serdemetan.html
Purity
99.56
Solubility
DMSO : 50 mg/mL (ultrasonic)
Smiles
C1(NCCC2=CNC3=C2C=CC=C3)=CC=C(C=C1)NC4=CC=NC=C4
Molecular Formula
C21H20N4
Molecular Weight
328.41
Precautions
H315, H319, H320
References & Citations
[1]Chargari C, et, al. Preclinical assessment of JNJ-26854165 (Serdemetan), a novel tryptamine compound with radiosensitizing activity in vitro and in tumor xenografts. Cancer Lett. 2011 Dec 22;312 (2) :209-18. |[2]Lehman JA, et, al. Serdemetan antagonizes the Mdm2-HIF1α axis leading to decreased levels of glycolytic enzymes. PLoS One. 2013 Sep 6;8 (9) :e74741. |[3]Jones RJ, et, al. The novel anticancer agent JNJ-26854165 induces cell death through inhibition of cholesterol transport and degradation of ABCA1. J Pharmacol Exp Ther. 2013 Sep;346 (3) :381-92.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Phase 1

Alternative Products

CatalogName
BUP09761-01Serdemetan
A4204-100JNJ-26854165 (Serdemetan)
C16160-100mgSerdemetan (JNJ-26854165)

Popular Products